At 24 weeks , ten ( 15 % ) patients in the pasireotide 40 mg group and 13 ( 20 % ) patients in the pasireotide 60 mg group achieved biochemical control , compared with no patients in the active control group ( absolute difference from control group 154 % , 95 % CI 76-265 , p = 00006 for pasireotide 40 mg group , 200 % , 111-318 , p < 00001 for pasireotide 60 mg group ) .